Gilles de la Tourette-Syndrome: Treatment of a neuropsychiatric disorder;Gilles de la Tourette-Syndrom: Behandlung einer neuropsychiatrischen störung

Praxis

Volumn 99, Issue 22, 2010, Pages 1353-1360

  Kawohl, Wolfram ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

Deep brain stimulation; Dopamine hypothesis; Gilles de la Tourette Syndrome; Guidelines; Pharmacotherapy

Indexed keywords

NEUROLEPTIC AGENT;

DRUG EFFICACY; DRUG THERAPY; GILLES DE LA TOURETTE SYNDROME; NEUROSURGERY; PSYCHOTHERAPY; SHORT SURVEY;

EID: 78149323429     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/1661-8157/a000294     Document Type: Short Survey

References (52)

1. Gilles de la Tourette G. Jumping, latah, myriachit. Archives de neurologie (Paris) 1884;8:68-74.
2. Gilles de la Tourette G. Étude sur une affection nerveuse caractérisée par de l'incoordination motrice accompagnée d'écholalie et de coprolalie. Archives de Neurologie (Paris). 1885;9:19-42,158-200.
3. Kawohl W, Podoll K. Contour copying or echoplasia - a new echo phenomenon in a person with Gilles de la Tourette syndrome. Psychopathology 2008; 41:201-202. (Pubitemid 351555835)
4. Freeman RD, Zinner SH, Muller-Vahl KR, et al. Coprophenomena in Tourette syndrome. Dev Med Child Neurol 2009;51:218-227.
5. Leckman JF. Phenomenology of tics and natural history of tic disorders. Brain Dev 2003;25 Suppl 1:S24-28. (Pubitemid 39658646)
6. Coffey BJ, Park KS. Behavioral and emotional aspects of Tourette syndrome. Neurol Clin 1997;15:277-289. (Pubitemid 27202914)
7. Tanner CM, Goldman SM. Epidemiology of Tourette syndrome. Neurol Clin 1997;15:395-402. (Pubitemid 27202922)
8. Robertson MM. Tourette syndrome, associated conditions and the complexities of treatment. Brain 2000;123: 425-462. (Pubitemid 30099531)
9. Freeman RD, Fast DK, Burd L, et al. An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Dev Med Child Neurol 2000;42:436-447. (Pubitemid 30427051)
10. Seignot JN. [A case of tic of Gilles de la Tourette cured by R 1625.]. Ann Med Psychol (Paris) 1961;119: 578-579.
11. Kurlan R. Tourette's syndrome and "PANDAS": will the relation bear out? Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection. Neurology 1998;50:1530-1534.
12. Pavone P, Parano E, Rizzo R, Trifiletti RR. Autoimmune neuropsychiatric disorders associated with streptococcal infection: Sydenham chorea, PANDAS, and PANDAS variants. J Child Neurol 2006;21:727-736. (Pubitemid 44696718)
13. O'Rourke JA, Scharf JM, Yu D, Pauls DL. The genetics of Tourette syndrome: a review. J Psychosom Res 2009;67:533-545.
14. Leckman JF, King RA, Cohen DJ. Tics and Tic Disorders. In: Leckman JF, Cohen DJ (eds). Tics, obsessions, compulsions: Developmental psychopathology and clinical care. Wiley and Sons: New York, 1999, 23-42.
15. Lerner A, Bagic A, Boudreau EA, et al. Neuroimaging of neuronal circuits involved in tic generation in patients with Tourette syndrome. Neurology 2007;68:1979-1987. (Pubitemid 46869701)
16. Bohlhalter S, Goldfine A, Matteson S, et al. Neural correlates of tic generation in Tourette syndrome: an event-related functional MRI study. Brain 2006;129:2029-2037. (Pubitemid 44289068)
17. Kawohl W, Bruhl A, Krowatschek G, Ketteler D, Herwig U. Functional magnetic resonance imaging of tics and tic suppression in Gilles de la Tourette syndrome. World J Biol Psychiatry 2009;10:567-570.
18. Neuner I, Kellermann T, Stocker T, et al. Amygdala Hypersensitivity in Response to Emotional Faces in Tourette's Patients. World J Biol Psychiatry 2010 [Epub ahead of print].
19. Snyder SH, Taylor KM, Coyle JT, Meyerhoff JL. The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs. Am J Psychiatry 1970;127:199-207.
20. Müller N, Riedel M, Krampe K. Tics. In: Jahn T (Hrsg.). Bewegungsstörungen bei psychischen Erkrankungen. Springer-Verlag: Berlin Heidelberg, 2004, 215-231.
21. Stillman A, Ercan-Sencicek AG, State MW (eds.). Tourette Disorder Overview. Gene Reviews [Internet], ed. R.A. Pagon, et al. 2009, University of Washington: Seattle (WA).
22. Cavanna AE, Servo S, Monaco F, Robertson MM. The behavioral spectrum of Gilles de la Tourette syndrome. J Neuropsychiatry Clin Neurosci 2009;21:13-23.
23. Muller-Vahl K, Dodel I, Muller N, et al. Health-related quality of life in patients with Gilles de la Tourette's syndrome. Mov Disord;25:309-314.
24. Müller N, Straube A, Horn B, Müller-Spahn F, Ortner M. Zwänge als Leitsymptom des Gilles-de-la-Tourette-Syndroms: Ein Beitrag zur Differentialdiagnose des Zwangssyndroms. Nervenheilkunde 1988;7:226-232.
25. Neurologie DGf. Leitlinien für Diagnostik und Therapie in der Neurologie. Vol. 4. 2008, Stuttgart: Georg Thieme Verlag
26. Rothenberger A, Banaschewski T, Roessner V. Ticstörungen (F95). In: d. Bundesarbeitsgemeinschaft leitender Klinikärzte f. Kinder- u. Jugendpsychiatrie u. Psychotherapie u. d. Berufsverband der Ärzte für Kinder- und Jugendpsychiatrie und Psychotherapie Dt. Gesellschaft f. Kinder- u. Jugendpsychiatrie u. Psychotherapie (Hrsg.). Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. Deutscher Ärzte Verlag, 2007.
27. Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989;28:566-573. (Pubitemid 19196295)
28. Mesulam MM, Petersen RC. Treatment of Gilles de la Tourette's syndrome: eight-year, practice-based experience in a predominantly adult population. Neurology 1987;37:1828-1833. (Pubitemid 18026360)
29. Kawohl W, Schneider F, Vernaleken I, Neuner I. Chronic motor tic disorder and aripiprazole. J Neuropsychiatry Clin Neurosci 2009;21:224.
30. Kawohl W, Schneider F, Vernaleken I, Neuner I. Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in adult patients. World J Biol Psychiatry 2009;10:827-831.
31. Grunder G, Carlsson A, Wong DF. Mechanismof new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003;60:974-977. (Pubitemid 37222078)
32. Rössner V, persönliche Mitteilung.
33. Marsden CD. Drug treatment of diseases characterized by abnormal movements. Proc R Soc Med 1973;66:871-873.
34. Lipinski JF, Sallee FR, Jackson C, Sethuraman G. Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov Disord 1997;12:402-407. (Pubitemid 27216140)
35. Leckman JF, Cohen DJ, Detlor J, et al. Clonidine in the treatment of Tourette syndrome: a review of data. Adv Neurol 1982;35:391-401.
36. Scahill L, Erenberg G, Berlin CM, Jr., et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006;3:192-206. (Pubitemid 44061705)
37. Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005;65:1941-1949. (Pubitemid 43970115)
38. Gonce M, Barbeau A. Seven cases of Gilles de la tourette's syndrome: partial relief with clonazepam: a pilot study. Can J Neurol Sci 1977;4:279-283. (Pubitemid 8233975)
39. Singer HS, Wendlandt J, Krieger M, Giuliano J. Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology 2001;56:599-604. (Pubitemid 32209991)
40. Muller-Vahl KR, Schneider U, Kolbe H, Emrich HM. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 1999;156:495.
41. Kawohl W, Rössler W. [Cannabis and Schizophrenia: new findings in an old debate]. Neuropsychiatr 2008;22:223-229.
42. Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord 1994;9:347-349. (Pubitemid 24150125)
43. Marcks BA, Berlin KS, Woods DW, Davies WH. Impact of Tourette Syndrome: a preliminary investigation of the effects of disclosure on peer perceptions and social functioning. Psychiatry 2007;70:59-67. (Pubitemid 46920359)
44. Bergin A, Waranch HR, Brown J, Carson K, Singer HS. Relaxation therapy in Tourette syndrome: a pilot study. Pediatr Neurol 1998;18:136-142. (Pubitemid 28125411)
45. Wilhelm S, Deckersbach T, Coffey BJ, et al. Habit reversal versus supportive psychotherapy for Tourette's disorder: a randomized controlled trial. Am J Psychiatry 2003;160:1175-1177. (Pubitemid 41070980)
46. Mink JW, Walkup J, Frey KA, et al. Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord 2006;21:1831-1838. (Pubitemid 44848927)
47. Visser-Vandewalle V, Ackermans L, van der Linden C, et al. Deep brain stimulation in Gilles de la Tourette's syndrome. Neurosurgery 2006;58:E590.
48. Vandewalle V, van der Linden C, Groenewegen HJ, Caemaert J. Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of thalamus. Lancet 1999;353:724. (Pubitemid 29103812)
49. Diederich NJ, Kalteis K, Stamenkovic M, Pieri V, Alesch F. Efficient internal pallidal stimulation in Gilles de la Tourette syndrome: a case report. Mov Disord 2005;20:1496-1499. (Pubitemid 43072659)
50. Flaherty AW, Williams ZM, Amirnovin R, et al. Deep brain stimulation of the anterior internal capsule for the treatment of Tourette syndrome: technical case report. Neurosurgery 2005;57:E403; discussion E403.
51. Kuhn J, Lenartz D, Mai JK, et al. Deep brain stimulation of the nucleus accumbens and the internal capsule in therapeutically refractory Tourette-syndrome. J Neurol 2007;254:963-965. (Pubitemid 47222295)
52. Neuner I, Podoll K, Janouschek H, et al. From psychosurgery to neuromodulation: deep brain stimulation for intractable Tourette syndrome. World J Biol Psychiatry 2009;10:366-376.